Nantahala Capital Management LLC Has $3.01 Million Stock Holdings in Rallybio Corporation $RLYB

Nantahala Capital Management LLC decreased its holdings in Rallybio Corporation (NASDAQ:RLYB) by 37.3% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 188,422 shares of the company’s stock after selling 112,213 shares during the period. Nantahala Capital Management LLC’s holdings in Rallybio were worth $3,014,752 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. ADAR1 Capital Management LLC boosted its stake in shares of Rallybio by 4,411.1% in the 2nd quarter. ADAR1 Capital Management LLC now owns 926,352 shares of the company’s stock valued at $14,822,000 after purchasing an additional 905,817 shares during the last quarter. Renaissance Technologies LLC raised its stake in Rallybio by 16.9% during the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock worth $573,000 after buying an additional 120,892 shares during the last quarter. Citadel Advisors LLC raised its stake in Rallybio by 576.1% during the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock worth $219,000 after buying an additional 373,821 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Rallybio by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after buying an additional 2,996 shares during the period. Finally, Susquehanna International Group LLP lifted its holdings in Rallybio by 485.9% in the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after buying an additional 113,031 shares during the period. 90.34% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on RLYB shares. Wall Street Zen upgraded Rallybio from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Weiss Ratings raised Rallybio from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Wednesday, August 19th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the company has an average rating of “Hold”.

Rallybio Trading Up 0.3%

Shares of RLYB stock opened at $16.81 on Friday. The firm has a market capitalization of $89.26 million, a PE ratio of -3.87 and a beta of -0.90. The firm has a fifty day simple moving average of $16.27 and a two-hundred day simple moving average of $12.63. Rallybio Corporation has a 12 month low of $3.67 and a 12 month high of $17.57.

Rallybio (NASDAQ:RLYB) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($1.09) earnings per share for the quarter, beating the consensus estimate of ($1.28) by $0.19. Rallybio had a negative net margin of 911.07% and a negative return on equity of 40.53%.

Rallybio Profile

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.